We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Ultrasensitive Biosensor Detects Cancer

By LabMedica International staff writers
Posted on 04 Jun 2012
An ultrasensitive biosensor has been created that could open up new opportunities for early detection of cancer and personalized medicine tailored to the specific biochemistry of individual patients. More...


The device, which could be several hundred times more sensitive than other biosensors, combines the attributes of two distinctly different types of sensors, a mechanical sensor, which identifies a biomolecule based on its mass or size, and an electrical sensor that identifies molecules based on their electrical charge.

At Purdue University (West Lafayette, IN, USA) scientists found that the new sensor detects both charged and uncharged biomolecules, allowing a broader range of applications than either type of sensor alone. The sensor's mechanical part is a vibrating cantilever, a sliver of silicon that resembles a tiny diving board. Located under the cantilever is a transistor, which is the sensor's electrical part. The sensor maximizes sensitivity by putting both the cantilever and transistor in a "bias.” The cantilever is biased using an electric field to pull it downward as though with an invisible string.

In other mechanical biosensors, a laser measures the vibrating frequency or deflection of the cantilever, which changes depending on what type of biomolecule lands on the cantilever. Instead of using a laser, the new sensor uses the transistor to measure the vibration or deflection. In early cancer diagnostics, the sensor makes possible the detection of small quantities of DNA fragments and proteins deformed by cancer long before the disease is visible through imaging or other methods. The device is called a Flexure-field effect transistor (FET) biosensor. A key innovation is the elimination of a component called a reference electrode, which is required for conventional electrical biosensors, but cannot be miniaturized, limiting practical applications.

The authors concluded that there are broad ranges of applications that can benefit from the sensitivity gain of the biosensor. For example, the current genome sequencing schemes require polymerase chain reaction (PCR) amplification of DNA strands because of the lower sensitivity of existing biosensors. The high sensitivity of Flexure-FET can eliminate the requirement of multiplication step and hence reduce the cost of sequencing. The study was published on May 23 2012, in the Proceedings of the National Academy of Sciences of the United States of America.

Related Links:

Purdue University



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.